Orbimed Advisors had a stake in Glaukos Corp (NYSE:GKOS) even before its IPO. Its recent 13F filing indicates a large new public position in the ophthalmic medical technology company of 2.90 million shares valued at $83.98 million. Orbimed Advisors holds nearly 10% of the outstanding common shares of the company through this holding. The shares of Glaukos Corp (NYSE:GKOS) are trading 1.86% above their IPO price at $31.80, giving it a market cap of $1.02 billion. The medical technology company is engaged in the development of a glaucoma treatment with iStent Trabecular Micro-Bypass Stent as its main portfolio drug. It is used for the treatment of mild-to-moderate open-angle glaucoma in adult cataract patients. Glaukos Corp (NYSE:GKOS) is working on an advanced version of iStent Trabecular Micro-Bypass Stent called iStent inject Trabecular Micro-Bypass Stent, which is one-third the size of the previous device. The medical technology company has completed patient enrollment for the FDA’s pivotal Investigational Device Exemption (IDE) trial for the device. Thomas Burns, CEO of Glaukos Corp, said, “Our completion of the iStent inject U.S. pivotal trial patient enrollment and the achievement of our patient randomization goal marks another milestone towards introducing breakthrough technologies that can advance glaucoma patient care.” The medical technology company has attracted investments from several firms, including Israel Englander’s Millennium Management, which had 196,176 shares valued at $5.69 million in its portfolio.
Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) is another new addition in the healthcare portfolio of Samuel Isaly. The investment firm had 4.41 million shares valued at $80.86 million of the clinical-stage biopharmaceutical company in its portfolio. The medical technology company works in the cancer immunotherapy sector, developing targeted treatments based on the T-cell receptor platform. Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) announced the FDA’s acceptance of its investigational new drug (IND) application for its MAGE-A10 T therapeutic candidate. The MAGE-A10 antigens are common in patients with non-small cell lung cancer. James Noble, CEO of the company, said, “The FDA’s acceptance of this IND represents an important step in our strategy to identify and develop new T-cell-based immunotherapeutics to combat non-small cell lung cancer and other cancers…” Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) has received investments from money managers such as Arrowgrass Capital Partners, led by Nick Niell, which had 478,854 shares of the company valued at $8.78 million as of June 30, 2015.
Disclosure: None
